2015 mckinsey report patient data

by Alene Gottlieb I 3 min read

McKinsey&Company Report 2015: The role of big data in …

19 hours ago  · What big data means for patients, payers, and pharma . ... McKinsey&Company Report November 2015. 8 Like Comment Share. To view or add a comment, ... >> Go To The Portal


What's in McKinsey Quarterly 2015 number 3?

This issue of the Quarterly, available here as a PDF download, explores how companies can raise their digital capabilities, apply discipline to the innovation process, and more comprehensively guard against cyberattacks. Download the full issue of McKinsey Quarterly 2015 Number 3 (PDF–3.3MB).

What is the global media report 2015?

Our Global Media Report 2015 offers both high-level data and a granular look at the media industry around the world. It provides annual historical data from 2009 through 2014, along with forecasts from 2015 through 2019, on a country-by-country basis, for 12 major media categories and numerous sub-categories.

Can McKinsey’s top consultants usher in an era of exponential innovation in healthcare?

They could be key to ushering in an era of exponential innovation in healthcare. Matthias Evers is a senior partner in McKinsey’s Hamburg office, Lucy Pérez is a senior partner in the Boston office, Lucas Robke is a consultant in the Düsseldorf office, and Katarzyna Smietana is a senior knowledge expert and associate partner in the Wroclaw office.

image

Adherence varies widely among medications treating the same disease

As might be expected, adherence rates varied noticeably among the disease categories examined. Exhibit 1 shows adherence and persistence rates across diseases.

Factors that influence adherence

In analyzing data that included prescription, healthcare, and consumer variables, we gained preliminary insight into the types of factors that may be influencing adherence, which may play a role in explaining differences seen among different medications.

Spotlight on psoriasis

Psoriasis had the lowest median persistence rate among the diseases studied and substantial variations in both persistence and adherence levels among medications. Many brands in this disease area are accompanied by patient-support programs.

Implications for pharmaceutical and healthcare organizations

These insights have practical business implications for pharmaceutical companies, healthcare systems, and health practitioners, including the following:

Identifying and addressing the barriers to adherence using a 360-degree approach

Pinpointing the factors across the four dimensions of nonadherence is necessary to effectively address patient adherence. By analyzing integrated data, pharmaceutical and healthcare companies can group patients into microsegments based on the different factors identified and design tailored interventions to support them.

About the author (s)

Jason Hichborn is a specialist in McKinsey’s North American Knowledge Center; Sari Kaganoff is an associate partner in the New Jersey office, where Nisha Subramanian is a partner; and Ziv Yaar is a partner in the Boston office.

What is the big data revolution in healthcare?

The big-data revolution in US health care: Accelerating value and innovation. Big data could transform the health-care sector, but the industry must undergo fundamental changes before stakeholders can capture its full value.

What is the US federal government's vast store of health care knowledge?

Meanwhile, the US federal government and other public stakeholders have been opening their vast stores of health-care knowledge, including data from clinical trials and information on patients covered under public insurance programs. In parallel, recent technical advances have made it easier to collect and analyze information from multiple ...

What has pharmaceutical companies been doing over the last decade?

Over the last decade, pharmaceutical companies have been aggregating years of research and development data into medical databases, while payors and providers have digitized their patient records.

What is evidence based medicine?

Physicians have traditionally used their judgment when making treatment decisions, but in the last few years there has been a move toward evidence-based medicine, which involves systematically reviewing clinical data and making treatment decisions based on the best available information.

What percentage of GDP is health care?

After more than 20 years of steady increases, health-care expenses now represent 17.6 percent of GDP—nearly $600 billion more than the expected benchmark for a nation of the United States’s size and wealth. 1. 1.

How do patients play an active role in their own health?

Patients must be encouraged to play an active role in their own health by making the right choices about diet, exercise, preventive care, and other lifestyle factors. Right care. Patients must receive the most timely, appropriate treatment available.

Do patients benefit from research on exercise?

Patients will not benefit from research on exercise, for example, if they persist in their sedentary lifestyles.

image

A New Value Framework

Image
Health-care stakeholders are well versed in capturing value and have developed many levers to assist with this goal. But traditional tools do not always take complete advantage of the insights that big data can provide. Unit-price discounts, for instance, are based primarily on contracting and negotiating leverage. And lik…
See more on mckinsey.com

The Pathways in Action

  • Some health-care leaders have already captured value from big data by focusing on the concepts outlined in our pathways or have set the groundwork for doing so. Consider a few examples: 1. Kaiser Permanente has fully implemented a new computer system, HealthConnect, to ensure data exchange across all medical facilities and promote the use of electronic health records. The inte…
See more on mckinsey.com

Improvement at Scale: What Is The Potential?

  • To determine the opportunity of the new value pathways, we evaluated a range of health-care initiatives and assessed their potential impact as total annual cost savings, holding outcomes constant, using a 2011 baseline. If these early successes were scaled up to create systemwide impact, we estimate that the pathways could account for $300 billion to $450 billion in reduced …
See more on mckinsey.com

A Few Caveats

  • Although we are optimistic about big data’s potential to transform health care, some structural issues may pose obstacles. The move away from fee-for-service care—already well under way—must continue. Similarly, traditional medical-management techniques must change, since they pit payors and providers against each other, framing benefit plans with respect to what is a…
See more on mckinsey.com